论文部分内容阅读
对腺病毒基因组进行改造可以使其特异性杀伤肿瘤细胞而不影响正常细胞,由此构建的溶瘤腺病毒(又称条件复制型腺病毒)(conditionally replicative adenoviruses,CRAds)作为癌症病毒治疗的方法之一已经应用于临床试验。然而病毒溶瘤作用不强限制了其进一步应用,目前多数的研究设计在溶瘤腺病毒内加载治疗基因,以增强其杀伤作用和对肿瘤微环境或免疫系统的调节,同时合理联合已有治疗方法,可提高溶瘤腺病毒抗肿瘤作用。
Adenovirus genomes can be modified so that it can specifically kill tumor cells without affecting normal cells. The resulting oncolytic adenoviruses (CRADs) have been used as cancer virus therapies One of them has been used in clinical trials. However, the role of the virus oncolytic is not strong enough to limit its further application. At present, most research designs to load the therapeutic gene in the oncolytic adenovirus so as to enhance its killing effect and regulation of the tumor microenvironment or the immune system, and to rationally combine the existing treatments Method can improve oncolytic adenovirus anti-tumor effect.